LYON, France - ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces the addition of a new product development candidate, ERY-MET, to the company’s tumor starvation product pipeline.

Tumor cells, unlike normal cells, are described to be dependent on the external supply of certain amino acids due to their inability to synthesize them. The full or partial depletion of these amino acids from the circulation deprives these tumor cells from required nutrients and can induce tumor starvation. The enzymes that perform the degradation of these amino acids often have a short half-life and are frequently associated with high levels of side effects. Encapsulating them in red blood cells can extend their half-life and reduce their toxicity.

This principle has been demonstrated in clinical studies with GRASPA®/ERY-ASP 1, the company’s lead product, currently in Phase III in Acute Lymphoblastic Leukemia (ALL). ERY-ASP consists of asparaginase encapsulated in red blood cells and acts on the systemic depletion of asparagine.

In parallel with the development of ERY-ASP, ERYTECH has over the past years actively investigated other therapeutic compounds targeting tumor starvation that benefit from encapsulation in red blood cells. The company is the beneficiary of a EUR 7 million French government funding to achieve this goal 2.

This has now resulted in the identification of a new product candidate, ERY-MET, consisting of Methionine-γ-lyase (MGL) encapsulated inside red blood cells. MGL breaks down the amino acid methionine, and has the potential to induce tumor starvation in multiple cancer indications by depletion of this amino acid. MGL in its natural form has a very short half-life and is highly dependent on a co-factor which is especially contained inside the red blood cells. With its proprietary encapsulation technology, ERYTECH has succeeded the encapsulation of MGL inside red cells with a good stability. The in vivo half-life of the encapsulated enzyme was extended to multiple days from a few hours for the free form.

Based on these promising preclinical results, the company will continue with the preclinical development and progress it to the stage of clinical testing. The industrial scale-up of the manufacturing will be initiated in the coming months to enable a first-in-man Phase I study in 2015. ERYTECH’s manufacturing facility is fully equipped to produce ERY-MET. The product is protected by the company’s core patents and a specific patent application.

“We are very motivated to develop this new and promising product encapsulating MGL and confirming the potential of our technology to encapsulate therapeutic compounds in red blood cells. The red blood cells are certainly the most suitable vehicle for MGL because this enzyme is highly dependent on a co-factor, a form of vitamin B6, which is especially contained inside the red blood cells,” comments Dr Yann Godfrin, co-founder and Chief Scientific Officer of ERYTECH Pharma.

“This project enters well into our IPO strategy, which consists of creating a strategic value by pursuing the development of ERY-ASP in liquid and solid tumors, all in broadening the application scope of our proprietary technology and extending our product portfolio in oncology,” adds Gil Beyen, Chairman and CEO of ERYTECH Pharma.